Journal of internal medicine
-
Randomized Controlled Trial
Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial.
Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and adverse events. ⋯ Several risk factors for ADAb formation during early-phase infliximab treatment were identified. This knowledge provides a basis for treatment strategies to mitigate the formation of ADAb and identify patients in whom these measures are of particular importance.